BetterRx

Short answer: Maybe — it depends on your BMI, medical conditions, and your clinician/insurer. Needing to lose 20 lb by itself isn’t the formal criterion. What doctors and insurers usually use For FDA-approved chronic weight‑loss indication, GLP‑1 drugs are usually prescribed when: BMI ≥ 30 kg/m2 (obesity), or BMI ≥ 27 kg/m2 plus at least one weight‑related comorbidity (type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, etc.). Some GLP‑1s (Ozempic, Mounjaro) are approved for type 2 diabetes even at lower BMIs, and clinicians sometimes prescribe them “off‑label” for weight loss for patients who don’t meet the obesity thresholds — but insurers rarely cover off‑label use. Your height and current weight determine whether a 20‑lb loss puts you into the qualifying/clinical range. Examples to help you judge If you’re 5'6" and currently 170 lb, your BMI is ~27.4 — that’s in the overweight range; you’d qualify for medication under BMI ≥27 only if you have a weight‑related comorbidity. If you’re 5'6" and 190 lb (BMI ~30.7), you meet the BMI ≥30 cutoff. Safety/contraindications (important) GLP‑1s aren’t appropriate if you’re pregnant, planning pregnancy, have a personal/family history of medullary thyroid cancer or MEN2, or have certain pancreatitis/GI conditions. Side effects include nausea, diarrhea, constipation, and rarely more serious problems. You need baseline labs and follow‑up (blood glucose if diabetic, kidney function, etc.). Which drugs/brands and why Wegovy (semaglutide) — FDA‑approved specifically for chronic weight management; strong evidence for substantial weight loss when combined with lifestyle change. Zepbound (tirzepatide) — FDA‑approved for weight management (liraglutide/semaglutide family’s stronger competitor); has shown large average weight reductions in trials. Ozempic (semaglutide) and Mounjaro (tirzepatide) — approved for type 2 diabetes and often cause weight loss; may be used off‑label for weight management but coverage varies. Rybelsus (oral semaglutide) — oral option (for diabetes); may be considered for those preferring pills, though weight‑loss formulations are injectables. Other prescription options for more modest weight loss Phentermine (short‑term), Qsymia (phentermine/topiramate), Contrave (naltrexone/bupropion), or Xenical (orlistat) — these may be appropriate alternatives depending on your health profile and goals. Where to go next (providers/services) Start with your primary care physician or an endocrinologist — they can calculate BMI, check for comorbidities, run needed labs, and advise on safety. If you want telemedicine options that evaluate and can prescribe GLP‑1s, consider services such as Ro (Roman), Hims & Hers, or Plenity/BetterRx programs. These services can be convenient for evaluation and ongoing prescriptions but check reviews, pricing, and whether they will coordinate labs and follow‑up. For comprehensive care, consider a weight‑management clinic (hospital‑based programs like Cleveland Clinic or local academic centers) where dietitians, behaviorists, and medical specialists are involved. Practical considerations Insurance coverage usually requires documented BMI/comorbidity and prior weight‑loss attempts; off‑label prescriptions are often out‑of‑pocket and expensive. Manufacturer savings cards or patient assistance programs (Novo Nordisk for Wegovy/Ozempic, Eli Lilly for Zepbound/Mounjaro) may help reduce cost if you qualify. Use GoodRx to compare cash prices. If you want, tell me your height and current weight (and any medical conditions), and I’ll calculate your BMI and explain whether you’re likely to meet the common criteria and what next steps to take.

Mentioned in position 4 of 8